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Considerations and Preliminary Proposals for Defining
a Reference Case for Economic Evaluations in
Ankylosing Spondylitis
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ABSTRACT. Since healthcare resources are scarce, choices have to be made on how they will be allocated. The use
of economic evaluations using cost-effectiveness analyses has increased rapidly as policymakers have
realized their value in maximizing the population’s benefits (in terms of length of life and health status)
within a given budget. Following efforts by OMERACT to create reference case definitions for the con-
duct of economic evaluation in rheumatoid arthritis, osteoporosis, and osteoarthritis, we review various
methodological areas and research decisions that could benefit from a consensus between researchers,
clinicians, and drug developers in terms of an ankylosing spondylitis (AS) reference case. Ten method-
ological issues are presented that will be important for future development of evaluations. Tentative pro-
posals to define the issues in a reference case for AS are made, along with recommendations for further
research. (J Rheumatol 2007;34:1178–83)
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Ankylosing spondylitis (AS) is a chronic inflammatory rheu-
matic disease that can have a progressive disabling course,
resulting in impaired physical functioning, work disability,
and reduced health related quality of life1-4. The recent
increase in attention to AS has come from findings that the
disease is nearly as prevalent and equally disabling as rheuma-
toid arthritis (RA)5,6, and the discovery that anti-tumor necro-
sis factor (TNF) therapy is highly effective in improving the
manifestations of the disease7.
Through improvements in patient function, therapy has the
potential to enhance health related quality of life and reduce
concomitant employment of healthcare resources8,9.
Consequently, a number of economic evaluations have esti-
mated whether the additional cost of spa therapy10, cyclooxy-
genase-2 (COX-2) selective inhibitors11, or TNF antago-
nists12-17 in patients with predominantly axial AS represent
worthwhile use of health resources. Such analyses are impor-
tant for government agencies and managed care groups when
deciding to allocate resources to new health technologies. Of
particular importance are decisions around expensive tech-
nologies like TNF antagonists, where use could result in a sig-
nificant increase in drug budgets. Given that economic evalu-
ations exist to inform decisions about resource allocation,
analyses should reflect what happens in the real world so trial-
based analyses or models based on a single randomized con-
trolled trial (RCT) usually represent only a partial and limited
form of analysis18. Decision-analytic models can be used to
combine multiple sources of evidence through systematic
review and metaanalysis, and can extrapolate evidence to time
horizons more useful for decision-making. However, such
models can be difficult to develop and, since they are based on
numerous methodological choices and assumptions, are open
to inaccuracy and bias19.
As a consequence, several guidelines are available for
those developing and performing economic evaluations20.
These provide direction on many generic issues in the conduct
of economic evaluations, and reflect the consensus within the
research community21. However, these guidelines are not spe-
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cific for particular health conditions or interventions. The
Outcome Measures in Rheumatology (OMERACT) initiative
has played a significant role in supporting the recommenda-
tion of disease-specific reference case definitions for the con-
duct of economic evaluation in RA, osteoporosis, and
osteoarthritis22,23. A reference case as defined by the US
Public Health Service Panel on Cost-Effectiveness is “a stan-
dard set of methodological practices that an analyst would
seek to follow in a cost-effectiveness study.”24 OMERACT is
considering expanding these efforts to include AS, and this
article describes the achievements in this direction to date.
Process
Many assumptions and choices have to be made when devel-
oping an economic evaluation. Our objective was to identify
topics for which a number of alternative options exist for ana-
lysts developing economic evaluations of all current and
potential technologies, which could benefit from a consensus
between researchers, clinicians, and drug developers. A list of
candidate issues was based on issues raised by previous
OMERACT initiatives for other rheumatological condi-
tions21-23. The list was complemented with items from the
wider economic evaluation literature, which has seen
advances in methodology over the past few years. A system-
atic review of economic evaluations in AS was performed to
identify discrepancies between published analyses. These
articles and 4 abstracts were appraised and helped to focus the
issues that would benefit most through consensus25. Next, a
Web-based questionnaire was developed containing each can-
didate issue with possible consensus options, along with an
open question to allow additional issues to be included. Over
30 invited experts returned a completed questionnaire.
Finally, these issues and their possible definitions were the
focus of a discussion between rheumatologists, economists,
and other interested parties at the OMERACT 8 meeting in
2006. We present the 10 issues identified from this process.
Each is described with its relevance in AS. Preliminary rec-
ommendations are given and areas for further research are
identified (Table 1).
Methodological issues
1. Time horizon/Duration of followup. An important starting
point for all analyses is the time within which the benefits and
costs associated with an intervention are evaluated. Some pay-
ers prefer a short time horizon, since they have interest in only
the short-term influence of interventions as a result of the fre-
quent changes in health plans experienced by many employ-
ees. In contrast, many guidelines for economic evaluations
state that the time horizon should be long enough to identify
all longterm effects and costs20. For example, in AS, if it is
plausible that TNF antagonists can modify disease progres-
sion, then the effect of treatment could last for the duration of
a patient’s life and consequently only a lifetime perspective
would indicate future cost savings and improved quality of
life. If TNF antagonists only relieve symptoms temporarily,
and after withdrawal patients return quickly to their previous
disease state, as is the case in many physiotherapies or spa
therapies, then a lifetime perspective would not be necessary.
The relevance of the time horizon for anti-TNF in AS is
shown in the publication of Kobelt, et al12 in which the cost-
utility ratio decreased by more than 50% when the 2-year
result was extrapolated to 30 years. Selecting the appropriate
time horizon is relatively simple, but finding evidence to pop-
ulate such horizons is usually very difficult. The selection and
approaches to estimating these inputs are discussed below.
2. Duration of treatment. The duration that a treatment is
administered in a clinical trial usually does not reflect the
duration in real life. In a trial setting, the protocol will nor-
mally require a patient to continue treatment until the end of
the study. However, for some treatments, like TNF antagonist
therapy, real-life guidelines suggest that the patient must
achieve an initial response to be eligible to continue therapy26-
28. From an economic perspective, this approach avoids the
continued accrual of costs of expensive agents when patients
are showing little evidence of efficacy. After an initial
response, patients can withdraw from treatment in the real-life
setting for several reasons, e.g., insufficient effect, noncom-
pliance, side effects, death. Including withdrawal in the mod-
els has implications for the model structure and for populating
the model with appropriate sources of evidence that can pro-
vide estimates for withdrawal. The 2 published analyses of
TNF antagonists in AS give different estimates for the length
of time patients will remain on treatment. Boonen, et al
assume that patients remain on treatment only if they initially
respond to treatment, or until they relapse or have major toxi-
city over the duration of the model14. Response, defined as
reaching a state of < 4 on the Bath AS Disease Activity Index
(BASDAI), is populated initially through data from the clini-
cal trials, then later from observational data. In contrast,
Kobelt, et al in their basecase analysis assume all patients
withdraw from TNF antagonists after 12 weeks, but then they
model the longer-term effect of that period of therapy12. These
different approaches have a large effect on the predicted costs
associated with treatment.
3. Extrapolation of effects beyond treatment and/or trial dura-
tion.When extrapolation of effects beyond the duration of the
treatment and beyond the duration of clinical trials is deemed
appropriate, careful consideration of the disease in question,
knowledge of its natural course, and some longterm evidence
on the treatment effects are required. Different assumptions
about longterm benefits based on short-term evidence can
give widely varying results. In the base-case analyses, Kobelt,
et al assumed that after the initial 12 weeks of treatment, the
Bath AS Functional Index (BASFI) would progress at 0.07
points per year under usual care as well as in the active treat-
ment group12. Boonen, et al assumed that there would be no
change in the BASDAI in the usual-care group after the first
year, whereas relapse to high disease activity was possible
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throughout the 5 years in the active treatment group14.
Assumptions are not restricted only to the efficacy of the
intervention, but also to what would happen once the patient
has withdrawn, and what the natural course of disease is for
the comparator arm. An example from the literature is the
“rebound” after withdrawal from treatment with TNF antago-
nists. Brandt, et al29 found that nearly all patients experienced
a relapse 24 weeks after stopping etanercept. If this relapse is
not correctly incorporated into the analysis, the extrapolation
could unfairly assume the intervention has longterm sustained
benefit, but without additional treatment costs30. Both Kobelt
and Boonen assumed patients under treatment would return to
the initial health state within 12 weeks. In line with this issue,
once patients are withdrawn from a particular treatment,
increasingly they move to another treatment, and sequences of
treatments might increasingly become clinical practice.
Jansen, et al describe the only study to look at this issue,
where nonresponders to COX-2 selective inhibitors are
assumed to move on to TNF antagonist treatment11.
4. Choice of comparator and synthesis of comparisons and
treatment strategies where clinical trials do not exist. The
question posed in most RCT where the active agent is com-
Table 1. Proposals and areas of further research for each issue identified.
Tentative Proposal Areas for Further Research
1. Time horizon/duration of followup
• The time horizon of an evaluation should be linked with the length of the •Along with further evidence on the longterm effectiveness of treatments, in
trial evidence that provides the primary source of effectiveness particular radiographic studies, understanding of the epidemiology of
• Taking into account comparability with the RA reference case, results other factors such as mortality and toxicity
should be reported at 1 year (DMARD and SMARD), 5 years, and
lifetime (DMARD only)
2. Duration of treatment
• Decision models should include an option for initial nonresponders for • The exact criteria used for assessing initial response require
whom therapy will be discontinued at a specified timepoint acknowledgement of economic as well as clinical consequences
• Registries should examine reasons and rates of withdrawal and mortality
and follow the sequence of treatments given to patients
3. Extrapolation of effects beyond treatment and/or trial duration
• Unless there is overwhelming evidence of the longterm benefits of treatment, • Registries and observational datasets should incorporate economic
a sensitivity analysis should always be presented that assumes that there is endpoints (HRQOL and costs)
no longterm effect
4. Choice of comparator and synthesis of comparisons and treatment strategies where clinical trials do not exist
• New economic models should always include the comparator “usual care” • Methods for making indirect comparisons, particularly when there is
• The absence of head-to-head studies should not restrict comparisons, heterogeneity in patient characteristics
although appropriate methods and sensitivity analysis should be used when
making indirect comparisons
5. Outcome measures
• Measures of both disease functioning and disease activity should be modeled • The components of clinical trials that best measure (1) clinical response,
(2) health improvements when on treatment, (3) progression
of disease, and (4) cost of illness if no treatment
6. Valuation of health in terms of quality of life or health utilities
• A generic health utility (health state preference) measure should be included •How to perform various (direct and generic) health utility instruments inAS
in clinical trials and registries • The relationship between changes in the clinical measures and changes
in health utilities in AS
7. Resource utilization and costing
• Estimates of the changes in productivity costs associated with an intervention • How productivity costs should be measured in AS and are there any
should not be included in the base-case result, but reported separately additional challenges posed in this disease?
as an alternative central result
8. Population risk stratification—subgroups
• Different subgroups of patients should be analyzed in economic models to • How subgroups of patients that are candidates for new interventions in
explore which groups are most cost-effective, but limitations in the evidence AS should be defined
should be clearly disseminated
9. Uncertainty analysis
• Extensive one-way sensitivity analysis should always be performed • How methods such as expected value of information can be used to direct
• Probabilistic sensitivity analysis should be used where the description further research in AS most efficiently?
of parameter uncertainty is possible, and the method is feasible
10. Model development and reporting
• All parameters associated with the model can be reported so the analysis is • How reproducible and therefore reliable are existing economic
transparent and reproducible. All assumptions should be reported explicitly. evaluations?
Where space does not allow in journal format, online appendices should be used
• All potential conflicts of interest should be reported and specific roles of each
author disseminated
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pared to placebo is that of efficacy, or “does the intervention
work?”. Economic evaluations have a different perspective,
that of effectiveness, or “how well does the intervention work
in comparison to the best conventional care?”. Currently, con-
ventional care in AS comprises nonsteroidal antiinflammatory
drugs (NSAID) and physical exercise. However, a proportion
of AS patients may not receive even this, having stopped see-
ing their physician, as until recently no disease modifying
treatments were available. Since primary RCT are unlikely to
compare new active compounds with existing active treat-
ments, data from secondary direct head-to-head studies would
be necessary to populate economic evaluations. Such trials are
unlikely to happen in the future since there is little incentive
for manufacturers to risk their market share, and the cost
would be too high for most public agencies.
Singh, et al15,17, Duff, et al16, and Boonen, et al14 use sim-
ple methods to compare the outcomes of the TNF antagonists
etanercept and infliximab either directly or indirectly by com-
paring to usual care, using results from separate clinical trials.
All methods follow an assumption regarding the comparabili-
ty of patient populations and some adjustment for the placebo
effect. New statistical methods have been developed to com-
pare multiple treatments that combine direct and indirect evi-
dence in a single analysis and to include Bayesian methods to
reduce uncertainty31,32.
3. Outcome measures. Essential for developing economic eval-
uations is the choice of the disease related specific health or
disease states that represent, clinically and economically,
important events in the disease process that is to be modeled.
In AS, several patient-reported outcomes are available. Among
these, the BASDAI33 and BASFI34 are most frequently used.
However, there is insufficient evidence on which (combination
of) measures reflect clinical and economic outcomes most ade-
quately. Further, response criteria for short-term treatment and
biologics have been defined by the ASsessment in AS (ASAS)
study group. In economic evaluations, absolute outcome meas-
ures are much preferred to relative response criteria, especial-
ly in longterm studies. Boonen, et al used 2 levels of the BAS-
DAI to describe the clinical health state, and included toxicity
as a separate state14. However, having just 2 states limits the
discriminative ability of an analysis to reveal changes in dis-
ease over time. Since the BASDAI does not measure domains
of physical functioning, Kobelt, et al used combined states of
BASDAI with the BASFI12.
6. Valuation of health in terms of quality of life or health utili-
ties. Among all study types, cost-utility analyses, whereby
health benefits are quantified in terms of quality-adjusted life-
years (QALY), are recommended in the great majority of
health economics guidelines as the method of choice for allow-
ing economic comparison between diseases24. Preference-
weighted measures are preferred using societal tariffs, and can
be collected using a variety of generic indirect utility instru-
ments, such as the Health Utilities Index, EQ-5D, or SF-6D.
In AS, the effect on quality of life (the quality adjustment)
is more notable than length of life (life-years)35,36. While it is
already difficult to identify all these effects of the disease in a
disease-specific QOL instrument, it is unlikely these are ade-
quately identified in the generic QOL instruments and indirect
utility instruments.
Importantly, instruments to calculate the indirect utilities
are not all comparable. The “floor effect” in the SF-6D has
shown that the instrument is not discriminative or responsive
in differences between severe states37. While the EQ-5D does
not suffer from such a floor effect, its sensitivity is more lim-
ited. In the published analyses, both Kobelt, et al12 and
Boonen, et al14 mapped the clinical outcomes onto EQ-5D
utilities.
7. Resource utilization and costing. AS carries a significant
economic burden, driven by productivity loss, ambulatory
care, and formal (and informal) care8,12,38. The societal per-
spective, which is widely considered to be the most appropri-
ate from an economic point of view, requires all components of
costs to be included in the economic evaluation, regardless of
who bears these costs. While previous work on the develop-
ment of standardized cost domains was mostly for patients
with RA, it should also be appropriate for patients with AS39.
Since AS affects many people of working age, a large propor-
tion of the costs attributable to AS is from work disability40,41.
The inclusion or exclusion of productivity costs and the choice
of method to calculate productivity costs (friction costs or
human capital approach) can influence the cost-utility ratios in
economic evaluations importantly. One study shows that when
indirect costs were included (using the human capital
approach), the cost-effectiveness ratio decreased by over
50%12. Even if it is feasible to measure all direct and indirect
costs directly during a (short) clinical trial, these costs can be
subject to the selection bias of patients recruited into most clin-
ical studies. An alternative is to use an observational study that
collects resource utilization data to populate the health states in
the model. An example of this is the work by Kobelt, et al,
which found disease activity measured using the BASDAI had
a strong influence on costs at non-severe levels, while the
BASFI caused costs to increase as the disease worsened12.
8. Population risk stratification — subgroups. Interventions
may have differential effects within the AS population,
depending on the disease characteristics of the group. Within
the population of patients with predominantly axial AS, for
which this reference case is aimed, subgroup analysis can be
used to identify populations in whom the target intervention
benefits the most. However, it is necessary to ensure that the
choice of subsample is justified where there is a priori a sound
biological rationale for doing so and where there is evidence
that clinical effectiveness or cost-effectiveness may vary
between groups, and that it was not chosen after “data dredg-
ing” to try to identify the subsample that yielded the most
favorable results in terms of the cost-effectiveness. The cred-
ibility of a subgroup analysis can be improved if confined to
the primary outcome and to a few predefined subgroups on the
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2007. All rights reserved.
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basis of biologically plausible hypotheses. In AS, potentially
relevant subsamples would be based on the disease duration,
level of disease activity, amount of radiographic damage,
number of prior therapies, and other recognized prognostic
factors for poor outcomes for axial disease such as uveitis or
hip arthritis42,43. In the review, we found that no subgroup
analyses have been performed in published analyses.
In addition, some interventions may have a benefit beyond
that of AS. In the case of TNF antagonists, it has been sug-
gested that patients with comorbidities such as presence of
inflammatory bowel disease, uveitis, psoriasis, and peripheral
arthritis might also receive benefit. By contrast, while NSAID
may also prevent radiological damage, they may increase the
risk of cardiovascular and gastrointestinal disease44.
9. Uncertainty analysis. It is not generally considered appro-
priate to truncate economic evaluations just because we are not
certain about specific parameters45; for example, if the analy-
ses on TNF antagonists in AS were restricted to using just the
short-term evidence. The current analyses suggest that TNF
antagonists would not be considered cost-effective interven-
tions. However, by using reasonable synthesis of data from
external sources, the longterm benefits of treatments can be
considered, and the cost-effectiveness appears more promis-
ing. However, sensitivity analysis shows that if specific param-
eters are changed to other reasonable scenarios or values, the
cost-effectiveness can change dramatically. Therefore uncer-
tainty in the extrapolations leads to uncertainty in the results.
The past decade has seen the development of more com-
prehensive methods to understand the implications of uncer-
tainty. By assigning a probability distribution to each parame-
ter to describe its range of plausible values and by using tech-
niques such as Monte Carlo simulation, the results can be pre-
sented as the probability that an intervention is cost-effec-
tive46. As an example, if the benefit of treatment is extrapo-
lated beyond the available clinical evidence, the full range of
what future benefits might be (say, from no prolonged effect
to continued constant effect) can be built into the analysis and
therefore into the decision. Of even more value is the ability
to quantify whether, for each parameter, it would be more
financially prudent to fund further research to reduce the
uncertainty in that parameter or to risk the financial impact of
making the wrong decision47. In published analyses, univari-
ate but not multivariate sensitivity analyses have been per-
formed, nor have any analyses used more sophisticated tech-
niques to analyze the uncertainty or prioritize future research.
10. Model development and reporting. The last issue consid-
ers how investigators develop and disseminate their analysis.
The need for transparency by detailing every parameter and
assumption, either in the journal article or as an appendix, is
universally accepted, but rarely adhered to48. Since most eval-
uations focus on a specific country, this becomes even more
important for the generalizability of results to other healthcare
settings. Our review found the published articles on the whole
were disappointing in this respect.
Conclusion
The economic implications of AS, in particular since the
advent of TNF antagonists, have caused much interest49.
Interventions for AS will compete for funding with other
interventions in other diseases and so the role of cost-effec-
tiveness analyses to evaluate the efficiency of treatments will
become even more important. Economic evaluations will only
be useful to inform decision-making and help guide further
research if they are of good quality.
A number of important issues are raised in this article. We
make tentative proposals on each issue (Table 1), and define
areas of further research that would improve economic evalu-
ations and their development in the future. It is likely that
future clinical research will have to pay more attention to the
economic considerations of interventions, through more prag-
matic trials and collecting new endpoints. The hope is that
future economic evaluations in AS will be of better quality,
more transparent, and comparable. With further discussion
and deliberation, we hope to develop a consensus-based refer-
ence case for future economic evaluations. The issues raised
here are by no means exhaustive, but are what we consider the
10 most important. Further work on the reference case will be
required to provide a definitive tool for use in AS.
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